WeVote
Log In

Bill

Bill

SB 542

Health: pharmaceuticals; choice of formulation, dosage, and route of administration for opioid antagonists by certain persons and governmental entities if department of health and human services distributes opioid antagonists free of charge; allow. Creates new act.

2023-2024 Regular Session Introduced by Rosemary Bayer and 9 co-sponsors

Michigan bill authorizes individuals and agencies to select opioid antagonist formulations/dosages when state distributes them free, aiming to increase overdose reversal access through consumer choice.

referred to second reading
#controlledsubstances:other #health:pharmaceuticals #stateagencies(existing):healthandhumanservices
0
WeVote Research Nonpartisan
Bill Summary · SB 542

Legislative bill overview

SB 542 would allow individuals and government entities to choose their preferred formulation, dosage, and delivery method (e.g., nasal spray vs. injection) for opioid antagonists (like naloxone/Narcan) when the Michigan Department of Health and Human Services distributes them for free. The bill establishes a new legal framework protecting these choices without liability concerns.

Why is this important

Opioid overdose deaths remain a significant public health crisis, and naloxone access is a proven intervention. This bill removes administrative barriers to broader naloxone distribution by clarifying that recipients can receive their preferred formulation—which may improve adoption rates and faster administration in emergency situations. However, choice and distribution costs must be balanced against practical supply chain management.

Potential points of contention

  • Cost and inventory complexity: Allowing unlimited formulation choices could complicate supply chain logistics and increase costs for state health departments managing free distribution programs
  • Clinical consistency vs. consumer preference: Some medical professionals argue standardized formulations ensure consistent training and outcomes, while advocates argue choice increases likelihood of actual use
  • Liability concerns: The bill's liability protections need clarity—who is responsible if someone chooses an inappropriate formulation or it's administered incorrectly?

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.